在大量饮酒的患者中,改善的肝纤维化得分在戒酒后保持稳定:试点研究
Thomas Lévi-Strauss1, Jocelyn Gal2, Eve Gelsi1
1Hepatology Unit, Archet 2 University Hospital, Nice, France.
Alcohol, clinical & experimental research
|April 15, 2024
概括
增强性肝纤维化 (ELF) 评分在戒酒后保持稳定,使其成为评估肝纤维化的可靠工具. 然而,第一周的临时增长需要仔细解释.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 临床化学 临床化学
- 与酒精有关的肝脏疾病
背景情况:
- 增强性肝纤维化 (ELF) 评分是慢性肝病中肝纤维化严重程度的经过验证的非侵入性标记.
- 它在戒酒期间的有用性,特别是在与酒精有关的肝病中,仍在研究中.
- 这项研究探讨了酒精戒断期间ELF得分的变化.
研究的目的:
- 为了评估在有过度饮酒史的患者中增强性肝纤维化 (ELF) 评分的变化,在戒酒期间饮酒过量.
- 为了确定ELF得分作为非侵入性生物标志物的稳定性和可靠性,在这种临床背景下.
主要方法:
- 一项前性试点研究,涉及35名有过度饮酒史的患者.
- 增强性肝纤维化 (ELF) 评分在基线 (D0),医院出院 (D7) 和停药后30 (D30) 和90 (D90) 天被测量.
- 暂时弹性图 (TE) 也在D4和D30进行了评估.
主要成果:
- 在90天期间,ELF得分在保持戒酒的患者和恢复饮酒的患者中显示稳定.
- 在戒断后的第一个星期 (D0到D7) 观察到过渡性,统计学上显著的ELF得分增加.
- 过渡性弹性图 (TE) 值在戒断或复发患者中显示D4和D30之间没有显著变化.
结论:
- 增强性肝纤维化 (ELF) 评分是一种稳定且可能有用的工具,用于评估酒精戒断患者的肝纤维化或肝硬化.
- 临床医生应谨慎地解释因暂时增加而导致戒断后第一周内ELF得分.
- 超过最初一周的ELF得分的稳定性支持其用于监测该人群中肝纤维化进展或回归的使用.
相关概念视频
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...


